BRAF and melanoma: The cytoplasmic intergenic lncRNA MIRAT (MAPK inhibitor resistance-associated transcript), instead, has been described as significantly over-expressed in melanoma cells, carrying NRAS or BRAF mutations, resistant to small molecule inhibitors of the MAPK cascade.